Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 11:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 163 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Retina Atrophy Clear all
Recruiting Phase 1Phase 2 Interventional

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07215234
View directory record Official record
Conditions
Geographic Atrophy
Interventions
SAR446597, Sham Comparator
Drug
Lead sponsor
Sanofi
Industry
Eligibility
60 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
14
States / cities
Peoria, Arizona • Scottsdale, Arizona • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 26, 2026, 11:53 AM EDT
Completed Not applicable Interventional Results available

COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy

NCT05961332
View directory record Official record
Conditions
Macular Degeneration, Age Related, Geographic Atrophy
Interventions
Spectralis FAF imaging, Optos imaging, Zeiss Clarus 700 imaging
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jun 26, 2026, 11:53 AM EDT
Recruiting Phase 2 Interventional

SGLT2 Inhibitors in Geographic Atrophy

NCT07174687
View directory record Official record
Conditions
Retinal Degeneration, Retinal Diseases, Eye Diseases, Geographic Atrophy, Pathological Conditions, Anatomical
Interventions
Dapagliflozin, Matching Placebo
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jun 26, 2026, 11:53 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

NCT06722157
View directory record Official record
Conditions
Macular Degeneration, Age-related, Geographic Atrophy
Interventions
BI 771716, Pegcetacoplan, Sham comparator to BI 771716
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
46
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 26, 2026, 11:53 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

NCT04002310
View directory record Official record
Conditions
Macular Degeneration
Interventions
BI 754132
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Beverly Hills, California • Pensacola, Florida • Winter Haven, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Jun 26, 2026, 11:53 AM EDT
Completed Phase 1Phase 2 Interventional

A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration

NCT01226628
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
CNTO 2476, iTrack Model 275 micro catheter
Biological · Procedure
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
50 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Arcadia, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Jun 26, 2026, 11:53 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

NCT04635800
View directory record Official record
Conditions
Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
Interventions
MHU650
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Huntington Beach, California • Honolulu, Hawaii • Hagerstown, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Jun 26, 2026, 11:53 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Ocular Proteomics Testing In Chronic Atrophy

NCT07298291
View directory record Official record
Conditions
Age-Related (Dry) Macular Degeneration
Interventions
AC Tap (anterior chamber paracenthesis)
Procedure
Lead sponsor
ClinOmicsAI
Network
Eligibility
50 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jun 26, 2026, 11:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD

NCT00766649
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Sirolimus
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Jun 26, 2026, 11:53 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Emixustat in Stargardt Disease

NCT03772665
View directory record Official record
Conditions
Stargardt Disease
Interventions
Emixustat, Placebo
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
16 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Beverly Hills, California • San Francisco, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Jun 26, 2026, 11:53 AM EDT
Completed Phase 2 Interventional Results available

A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

NCT02288559
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Sham, Lampalizumab
Other · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
60 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
36
States / cities
Mesa, Arizona • Tucson, Arizona • Springdale, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jun 26, 2026, 11:53 AM EDT
Completed No phase listed Observational Results available

Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)

NCT01272076
View directory record Official record
Conditions
Age Related Macular Degeneration, Geographic Atrophy
Interventions
Not listed
Lead sponsor
Carl Zeiss Meditec, Inc.
Industry
Eligibility
50 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Oakland, California • Jackson, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced Jun 26, 2026, 11:53 AM EDT
Active, not recruiting No phase listed Observational

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT06161584
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
34
States / cities
Bakersfield, California • Beverly Hills, California • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 26, 2026, 11:53 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Alpha Lipoic Acid in Geographic Atrophy

NCT02613572
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
alpha lipoic acid, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
Iowa City, Iowa • Teaneck, New Jersey • Eugene, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Jun 26, 2026, 11:53 AM EDT
Terminated Phase 2 Interventional

Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD

NCT02467634
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
HuCNS-SC sub-retinal transplantation
Biological
Lead sponsor
StemCells, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Tucson, Arizona • Beverly Hills, California • Campbell, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Jun 26, 2026, 11:53 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

NCT01694940
View directory record Official record
Conditions
Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes, Deletion and Duplication of Mitochondrial DNA
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
16
States / cities
San Diego, California • Stanford, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jun 26, 2026, 11:53 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

NCT06018558
View directory record Official record
Conditions
Geographic Atrophy
Interventions
OCU410
Genetic
Lead sponsor
Ocugen
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • Coral Springs, Florida • Carmel, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jun 26, 2026, 11:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

NCT07158775
View directory record Official record
Conditions
Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
Interventions
BS01, Sham procedure control
Biological · Other
Lead sponsor
Bionic Sight LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jun 26, 2026, 11:53 AM EDT
Terminated No phase listed Observational

Long-Term Follow-up Safety Study of Human Central Nervous System Stem Cells in Subjects With Geographic Atrophy of Age-Related Macular Degeneration

NCT02137915
View directory record Official record
Conditions
Age-Related Macular Degeneration, Geographic Atrophy
Interventions
Human Central Nervous System Stem Cells
Biological
Lead sponsor
StemCells, Inc.
Industry
Eligibility
51 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Jun 26, 2026, 11:53 AM EDT
Enrolling by invitation No phase listed Observational

Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

NCT06167642
View directory record Official record
Conditions
Multiple Sclerosis, Tomography, Optical Coherence, Retinal Degeneration, Visual Acuity
Interventions
Ofatumumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 26, 2026, 11:53 AM EDT
Completed Phase 1 Interventional Results available

Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy

NCT01003691
View directory record Official record
Conditions
Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration
Interventions
RN6G, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
24
States / cities
Campbell, California • Los Gatos, California • San Jose, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Jun 26, 2026, 11:53 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT02087085
View directory record Official record
Conditions
Geographic Atrophy, Macular Degeneration
Interventions
400 µg Brimonidine Implant, Sham
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
55 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
23
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Jun 26, 2026, 11:53 AM EDT
Completed No phase listed Observational

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD

NCT02463344
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
MA09-hRPE
Biological
Lead sponsor
Astellas Institute for Regenerative Medicine
Industry
Eligibility
55 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Jun 26, 2026, 11:53 AM EDT
Recruiting Phase 2 Interventional

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

NCT05626114
View directory record Official record
Conditions
Geographic Atrophy
Interventions
OpRegen
Biological
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
15
States / cities
Beverly Hills, California • Sacramento, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 26, 2026, 11:53 AM EDT